section name header

Indications ⬇

High Alert

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: peripheral edema, DEEP VEIN THROMBOSIS (DVT), MI

Derm: dry skin, hyperhidrosis, night sweats, pruritus, rash, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), skin exfoliation, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN)

Endo: hyperglycemia

F and E: F and E, hypercalcemia, hypocalcemia, hypokalemia, hyponatremia

GI: ↓appetite, constipation, diarrhea, nausea, vomiting, HEPATOTOXICITY

GU: renal failure

Hemat: anemia, leukopenia, lymphopenia, neutropenia, THROMBOCYTOPENIA

MS: arthralgia, back pain, bone pain, muscle spasms, muscle weakness, musculoskeletal pain, pain in extremity

Neuro: confusion, dizziness, insomnia, neuropathy, fatigue, STROKE, tremor, weakness

Resp: dyspnea, PULMONARY EMBOLISM (PE)

Misc: fever, infection, malignancy, chills, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Multiple Myeloma

Renal Impairment

Hepatic Impairment

Kaposi Sarcoma

Renal Impairment

Hepatic Impairment

US Brand Names ⬆ ⬇

Pomalyst

Action ⬆ ⬇

  • Inhibits proliferation and induced apoptosis of hematopoietic tumor cells. Proliferation of resistant multiple myeloma cell lines and may act synergistically with dexamethasone. Enhances T cell and natural killer cell-mediated immunity and inhibits production of proinflammatory cytokines.
Therapeutic effects:
  • Decreased progression of multiple myeloma and Kaposi sarcoma.

Classifications ⬆ ⬇

Therapeutic Classification: antineoplastics

Pharmacologic Classification: immunomodulatory agents

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed following oral administration.

Distribution: Enters semen.

Metabolism/Excretion: Primarily metabolized in the liver by CYP1A2 and CYP3A4 with some metabolism by CYP2C19 and CYP2D6. Metabolites excreted in urine and feces. Minimal amounts excreted unchanged in urine.

Half-Life: Normal subjects: 9.5 hr; Patients with myeloma: 7.5 hr.

Time/Action Profile ⬆ ⬇

ROUTEONSETPEAKDURATION
POunknownunknownunknown

Patient/Family Teaching ⬆ ⬇

  • REMS: Instruct patient to comply with all aspects of the PS-Pomalidomide REMS program. Details available at www.PS-PomalidomideREMS.com.
  • Explain purpose and side effects of medication to patient. Advise patient to read Patient Information before starting therapy. Instruct patient to take as directed daily at the same time each day. Missed doses may be taken up to 12 hr after the time it would be normally be taken. If >12 hr, skip dose and take regularly scheduled dose the next day; do not double doses.
  • Advise patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care provider before taking other medications.
  • Caution patient not to share pomalidomide with anyone, even someone who has similar symptoms.
  • Instruct patient to avoid smoking during therapy; may ↓ efficacy of pomalidomide.
  • Advise patient to notify health care provider if signs and symptoms of a blood clot (shortness of breath, chest pain, arm or leg swelling), heart attack (chest pain that may spread to arms, neck, jaw, back, or abdomen; feeling sweaty; shortness of breath; feeling sick or vomiting), or stroke (sudden numbness or weakness, especially on one side of body; severe headache or confusion; problems with vision, speech, or balance) occur.
  • Advise patient to notify health care provider if signs and symptoms of liver problems (yellowing of skin or white part of eyes, dark or brown urine, pain on upper right side of abdomen, unusual bleeding or bruising, feeling tired), skin reactions (red, itchy skin rash; peeling of skin; blisters; severe itching; fever), or allergic reaction (swelling of lips, mouth, tongue, or throat; trouble breathing or swallowing; very fast heartbeat; feeling dizzy or faint; hives) occur.
  • May cause dizziness and confusion. Caution patient to avoid driving and other activities requiring alertness until response to medication is known.
  • Advise patient to avoid donating blood while taking pomalidomide and for 1 mo following therapy.
  • Rep: May cause fetal harm. Inform women of reproductive potential that they must use one highly effective method (IUD, hormonal contraceptive, tubal ligation, partner’s vasectomy) and one additional method (latex or synthetic condom, diaphragm, cervical cap) for 4 wk before, during therapy and interruptions of therapy, and for 4 wk after last dose and to avoid breastfeeding during therapy. May impair female fertility. Encourage pregnant women and pregnant female partners of men exposed to pomalidomide during pregnancy to enroll in the registry to monitor outcomes of pregnancy by calling 1-888-423-5436. Pomalidomide is present in semen. Male patients receiving pomalidomide must always use a latex or synthetic condom during any contact with women of reproductive potential and for 4 wk after last dose, even if they have undergone a successful vasectomy. Instruct men to avoid donating sperm while taking pomalidomide and for 1 mo after last dose.

Pronunciation ⬆ ⬇

pom-a-LID-oh-mide

Code ⬆

NDC Code